



NAVY AND MARINE CORPS PUBLIC HEALTH CENTER
PREVENTION AND PROTECTION START HERE



Health Analysis
Navy and Marine Corps Public Health Center
620 John Paul Jones Circle
Portsmouth, VA 23708

[Name]
[Address]

June 1, 2013

Dear [Mr./Ms. Name]

In February of 2011, the Food and Drug Administration (FDA) required a new black box warning label on fluoroquinolone medications, due to a recently identified risk for those with myasthenia gravis. In some cases, the use of fluoroquinolone medications can worsen myasthenia gravis.

Because of this recently identified risk, the FDA requires labeling changes for the following fluoroquinolone medications:

- Avelox (moxifloxacin hydrochloride) Tablets and Avelox (moxifloxacin hydrochloride in NaCl injection) I.V.
- Cipro (ciprofloxacin hydrochloride) Tablets, Oral Suspension, IV and Cipro XR (ciprofloxacin extended-release tablets)
- Noroxin (norfloxacin) Tablets
- Levaquin (levofloxacin) Tablets, Oral Solution and Injection
- Proquin XR (ciprofloxacin) Extended-Release Tablets
- Floxin (ofloxacin) Tablets
- Factive (gemifloxacin mesylate) Tablets

In coordination with your healthcare provider and the Navy Bureau of Medicine, the Navy and Marine Corps Public Health Center is notifying you to take careful steps regarding the management of your healthcare. If you have been diagnosed with myasthenia gravis, please present the attached notification card and notify any provider of healthcare to you that medical treatment using fluoroquinolone medications may be harmful to your health. Retain the card for future use.

If you have further questions regarding fluoroquinolone treatment and your health, please contact your healthcare provider. Further information can also be found at the following website:

<http://www.med.navy.mil/sites/nmcphc/health-analysis/Pages/notifications.aspx>

Sincerely,

P. Rockswold
CAPT, MC, USN